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Abstract
The dominant hypothesis of Alzheimer’s disease (AD) aetiology, the neuropathological guidelines for diagnosing AD and 
the majority of high-profile therapeutic efforts, in both research and in clinical practice, have been built around one pos-
sible causal factor, amyloid-β (Aβ). However, the causal link between Aβ and AD remains unproven. Here, in the context 
of a detailed assessment of historical and contemporary studies, we raise critical questions regarding the role of Aβ in 
the definition, diagnosis and aetiology of AD. We illustrate that a holistic view of the available data does not support an 
unequivocal conclusion that Aβ has a central or unique role in AD. Instead, the data suggest alternative views of AD aetiol-
ogy are potentially valid, at this time. We propose that an unbiased way forward for the field, beyond the current Aβ-centric 
approach, without excluding a role for Aβ, is required to come to an accurate understanding of AD dementia and, ultimately, 
an effective treatment.
Our major goal must be the prevention of AD, and 
achievement of this goal requires that we first under-
stand its cause.
Katzman [138]
Background
The recent National Institute on Aging and Alzheimer’s 
Association (NIA-AA) Research Framework is an interest-
ing document [119]. Clearly, the words “a biological defini-
tion” in the title implies searching for biomarkers with an 
essential and defining functional role in the pathogenesis of 
Alzheimer’s disease (AD). Yet the text might read more as a 
commitment to keeping both the amyloid hypothesis and the 
amyloid removal concept of AD treatment in the forefront 
of the research agenda, rather than as the new approach the 
field awaits.
One cannot ignore the data supporting a possible role of 
amyloid-β (Aβ), nor rule out a plausible clinical rationale 
for removing it, but the present data does not prove Aβ has, 
or will have, a central role in AD nosology, aetiology or 
diagnosis. On the contrary, many would question whether, 
in the face of the extraordinary accumulation of inconsisten-
cies and controversies surrounding the amyloid hypothesis 
[179], and an accumulation of evidence that supports alter-
native views of aetiology [39, 43, 59, 176, 204, 220, 272], 
Aβ pathology should still be highly regarded as a biomarker 
that defines AD as a unique neurodegenerative disorder.
In fact, the literature indicates neither amyloid plaques, 
nor neurofibrillary tangle (NFT) deposits, are unique to AD, 
as suggested in their abstract [119], since these pathologies 
are also paired in other neurodegenerative states, such as 
post-stroke syndromes [268], Parkinson’s disease (PD) [203], 
traumatic brain injury (TBI) [140], HIV-dementia [288], 
Lewy body dementia [54] and lead poisoning [158]. Indeed, 
Alois Alzheimer and his contemporaries noted similarities 
in the clinical and pathological presentations of syphilitic 
dementia and AD [171]. These examples demonstrate how 
these conditions appear to be on the same pathophysiological 
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spectrum, as distinct from Aβ pathology being unique to an 
‘Alzheimer’s continuum’, as suggested [119].
There are at least nine modifiable risk factors for AD, all 
of which may reduce disease risk independently of Aβ and/
or tau pathology [161]. As noted [161], focussing on unique 
features in the whole person, rather than a single feature, is 
crucial to successfully altering the course of disease. We 
argue that this principle also applies as the AD field looks 
to define, and pharmacologically target, biological features 
of this disease. The rest of this text summarises how AD 
research was led into this Aβ-dominated cul-de-sac, and sug-
gests ways out of it.
The present definition, hypothetical models 
of aetiology and diagnostic criteria of AD 
may need reform
A lack of success of promising therapeutics for AD [65, 71, 
107, 231] has recently been reinforced by the departure of 
a discouraged Pfizer from the field. As ever, there is some 
hope in current trials [56]. Most notably, a recent comment 
from Biogen and Eisai hinted at promising Phase II results 
with an anti-Aβ drug [72], albeit with important caveats. 
Here, we debate the strengths and weaknesses of the experi-
mental evidence supporting current therapeutic efforts and 
discuss whether they are too heavily reliant on what may be 
a flawed approach to AD nosology, aetiology and diagnosis.
In particular, we discuss an insufficiently reflected point: 
that the current consensus neuropathological diagnostic 
strategy for AD is based on no more than a working hypoth-
esis of disease aetiology, underlined by two long-held, but 
unproven, assumptions (Box 1). We will illustrate that nei-
ther the historical, clinical, or preclinical records unequivo-
cally endorse the absolute validity of these assumptions 
(Box 1), or the amyloid hypothesis more generally. It follows 
that the record cannot currently support recently proposed 
research guidelines for the specific identification of pre-
clinical and prodromal states of AD, which are based on an 
extension of these assumptions [2, 255]. If the assumptions 
underlying the current predominant approach are indeed 
wrong, an overhaul is urgently required. Our discussion will 
focus on clinical AD research. We and others have reviewed 
the many continuing inconsistencies and controversies in 
preclinical studies [38, 39, 60, 179, 204, 220, 249, 272].
As will be seen, we do not suggest Aβ has no role in AD. 
Nevertheless, just as the effectiveness of H2 receptor antago-
nists and proton pump inhibitors led researchers astray on 
the centrality of stomach acid to stomach ulcers [165], cur-
rent evidence for a role of Aβ in AD, or potential positive 
results with anti-Aβ agents in humans, does not and will 
not necessarily point to Aβ as the central cause or accurate 
prognostic of AD dementia. The broader point is that this 
debate is now essential to reach a more accurate understand-
ing of AD.
Box 1: Long‑held assumptions supporting 
the hypothetical current consensus 
diagnostic guidelines for Alzheimer’s 
disease
Assumption 1 Aβ and tau pathologies are, combined, 
a specific marker of AD dementia  with  Aβ pathol-
ogy upstream of tau and other AD-associated pathologies.
Assumption 2 AD is a single homogenous disorder in 
which individuals with early-onset familial or early-onset 
sporadic AD (onset at < 65 years of age) and late-onset 
familial or late-onset sporadic AD (onset at > 65 years of 
age) have the same disease.
The current neuropathological diagnosis 
of AD propagates a hypothesis of disease 
aetiology
Initial clinico‑neuropathological diagnostic 
guidelines for AD were based on a hypothesis 
of aetiology
The nosology of tuberculosis, once based on the presence 
of tubercles, evolved when Mycobacterium tuberculosis was 
discovered as causative by Robert Koch (reviewed in [83]). 
AD research has similarly seen many ground-breaking dis-
coveries in the past 30 years, but the diagnostic guidelines 
and hypothetical framework of pathogenesis supporting these 
guidelines (the amyloid hypothesis) remain fixed in a percep-
tion of aetiology first elaborated, in earnest, during the 1980s.
In the late 1960s, Tomlinson, Roth and Blessed under-
took studies suggesting numerical scores of amyloid plaques 
and NFTs, two brain ‘lesions’ long associated with age and 
dementia (Fig. 1), correlated to scores of dementia [23, 222, 
269, 270]. This encouraged the idea that quantifying these 
lesions could be diagnostically useful to distinguish normal 
aging and dementia (Assumption 1, Box 1). This idea subse-
quently became a core feature of the first neuropathological 
diagnostic guidelines for AD, published in the 1980s [143, 
169] (see Supplementary Material 1.1 for important extended 
historical context on the development of AD nosology).
A second influential change was a 1976 editorial by 
Robert Katzman. Building on an earlier opinion from Mar-
tin Roth (discussed in [228]), he argued that aggressive 
presenile dementia (i.e. early-onset AD dementia begin-
ning at < 65 years of age, at the time labelled ‘Alzheimer’s 
disease’ in accordance with Emil Kraepelin’s original 1910 
definition [147]) was the same disease as senile dementia 
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(i.e. late-onset AD dementia beginning at > 65 years of age 
[137]). We later (Question 5) discuss whether Katzman’s 
view is still relevant in contemporary AD literature.
The clinico‑neuropathological diagnosis of AD 
remains based on a hypothesis of aetiology
The definition of AD as a cognitive disorder with amyloid 
plaques and NFTs essentially became the assumed truth in 
clinical practice and has driven research for decades. This 
concept drove the elucidation of the peptide constituent of 
the amyloid plaques (Aβ) [91, 92, 167] and of pathogenic 
mutations and duplications in the genes for the Aβ precur-
sor protein, amyloid precursor protein (APP) and mutations 
in proteins involved in the enzymatic processing of APP 
into various peptides (including Aβ), presenilin 1 and 2 
(PSEN1/2), in some familial AD cases [131].
Although NFTs were revealed to be composed of hyper-
phosphorylated tau protein [114] over this same period, 
identifying genetic links to APP and its processing enzymes 
drew attention firmly toward Aβ as a likely upstream cause 
of AD. From this focus evolved the ‘amyloid (or Aβ) 
(cascade) hypothesis’ (as well as a later iteration, the ‘Aβ 
oligomer hypothesis’ [52]), predicting that accumulated, 
aggregated or uncleared Aβ peptides, forming both soluble 
Aβ oligomers and insoluble amyloid plaques, are central to 
the onset and progression of AD. Indeed, as late as 2016 
this concept was still regarded as “…the most extensively 
validated and compelling therapeutic target in this disease” 
[244].
Many clinico-neuropathological studies followed, as did 
research with genetically modified mouse models expressing 
familial AD-linked APP and PSEN mutations, and intense 
in vitro and in vivo effort assessing the synaptic and neuro 
‘toxicity’ of Aβ. All this added fuel to the notion of Aβ cen-
trality [179] in autosomal dominant AD and by inference, 
sporadic AD. Thus, the amyloid hypothesis became a major 
pillar of the fundamental assumptions contained in the first 
diagnostic guidelines for AD (Box 1) [143].
The notion that Aβ pathology defines AD has remained 
largely intact through each successive update to the diag-
nostic criteria [28, 108, 109, 143, 170, 172]. Until now, a 
diagnosis of ‘typical’ AD dementia is first clinical, defined 
by the presence of a hippocampal amnestic syndrome, with 
Fig. 1  A chronological sequence of questions, assumptions and 
findings leading to the current Aβ-centric ‘consensus’ Alzheimer’s 
disease neuropathological diagnostic guidelines. Major observa-
tions, findings and assumptions have been distilled into the current 
‘consensus’ diagnostic guidelines for AD. In brief, these guidelines 
are derived from the hypothesis that the relative levels of amyloid 
plaques and NFTs in specific brain regions differentiates AD demen-
tia from normal cognitive aging. Combined with the amyloid hypoth-
esis they predict Aβ and  tau pathology to be a specific marker of 
AD at symptomatic and possibly preclinical and prodromal stages, 
with Aβ considered causative of tau pathology (and other AD-associ-
ated pathologies). NFTs neurofibrillary tangles, Aβ  amyloid-β
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or without other cognitive and behavioural changes [68, 
289]. This is corroborated, after obvious clinical exclusion, 
by in vivo or end-stage quantification of cerebral Aβ pathol-
ogy, adjusted for age.
Although NFT counts are also still an essential part of 
the neuropathological diagnosis of AD (e.g. Braak stag-
ing of NFT pathology [68, 108]), the amyloid hypothesis 
predicts they and other disease-associated pathologies, 
including synapse degeneration, hippocampal atrophy and 
neuroinflammation, are downstream of Aβ pathology and 
less disease specific [119, 189, 236]. Therefore, if an indi-
vidual presents with the clinical symptoms of AD dementia 
without cerebral Aβ pathology, the current view posits that 
individual simply does not have AD. This is a ‘consensus’ 
view broadly shared by both the NIA-AA diagnostic guide-
lines (2011–2018) [108, 119, 170, 175] and the International 
Work Group (IWG) criteria (2007–2014) [67, 68], which 
has been passed down from the 1980s guidelines [143, 169] 
and subsequent updates to them [28, 109, 172]. The amy-
loid hypothesis continues to support these guidelines, being 
firmly stated as the favoured hypothesis of AD aetiology by 
a recently commissioned NIA-AA workgroup [119].
A litany of data leads to questions 
regarding the robustness of the assumption Aβ 
pathology is disease defining
The emergence of AD diagnostic criteria in the 1980s, in 
conjunction with the amyloid hypothesis, meant that, over 
the ensuing decades, ‘Aβ pathology’ has essentially become 
synonymous with ‘Alzheimer’s’. In practice, irrefutably 
proving the amyloid hypothesis or, more accurately, reject-
ing the null hypothesis that Aβ is not causally linked to AD 
dementia, has not yet occurred. Thus, the current neuro-
pathological diagnosis of AD dementia is in fact a diagnosis 
of a working hypothesis of disease aetiology (for historical 
comments regarding the formation of the initial diagnostic 
guidelines in 1984/1985 see [144]). Additionally, as we dis-
cuss throughout, a litany of data has consistently emerged 
to question the robustness of the Aβ-centric view of AD 
dementia, leading to a loss of confidence in the amyloid 
hypothesis by many researchers [14, 38, 40, 43, 148, 185, 
204, 253, 272].
All this matters because the strategy used to diagnose dis-
ease has ethical, societal and financial consequences through 
determining treatment strategies and research funding deci-
sions, and moulding public opinion and health policies 
[216]. Increasingly, therefore, decisions based on the amy-
loid hypothesis are not to be taken lightly. In this context, 
very recent recommendations, published in 2016 [69] and 
2018 [119] for predicting disease in preclinical (‘at-risk’) 
stages, using in vivo measurements of putative AD biomark-
ers, concern us.
The extension of hypothetical diagnostic 
guidelines to preclinical and prodromal 
states
The push to extend hypothetical diagnostic criteria 
for AD to preclinical and prodromal phases may 
be premature whilst the assumptions underlying 
the criteria remain unproven
In 2011 recommendations were published for identifying 
prodromal (‘mild cognitive impairment (MCI) due to AD 
[2]’) and preclinical (‘AD-pathophysiological process [255]’) 
stages of AD. Subsequently, proposals that these stages could 
be identified using in vivo ‘biomarker’ evidence of Aβ and tau 
pathology, irrespective of cognitive changes, have emerged.
The recent NIA-AA commissioned workgroup consoli-
dated these proposals, and spoke of an ‘Alzheimer’s contin-
uum’ [119]. This was defined as: “…individuals with bio-
marker designation of either AD or Alzheimer’s pathologic 
change”, wherein “biomarker designation of AD” refers to 
in vivo evidence of Aβ and tau pathology and “Alzheimer’s 
pathologic change” refers to in vivo evidence of Aβ pathology 
alone (with normal tau biomarkers). In this system, evidence 
of abnormal tau and/or neurodegeneration biomarkers, in the 
absence of Aβ pathology, are defined as "non-AD pathologic 
change". Importantly, the IWG have also proposed guidelines 
for the identification of these states with the use of biomarkers 
[69], but are less definitive than the NIA-AA workgroup on the 
primacy of Aβ measurements. They still allow for the possibil-
ity that those with evidence of tau pathology, in the absence 
of amyloid, are also at-risk for AD dementia [69]. As noted 
[119], the two advisory bodies are, however, harmonised on 
the concept of using the label ‘Alzheimer’s’ when Aβ and tau 
pathology are found, irrespective of the cognitive diagnosis.
Collectively therefore, these proposals appear to argue for 
the terms ‘Alzheimer’s continuum’, ‘Alzheimer’s Disease’ or 
‘at-risk for Alzheimer’s’ being used only when Aβ (and, in 
the case of the IWG, tau) pathology is detected, irrespective 
of a clinical diagnosis or age. In turn, without such evidence, 
it is proposed the label ‘Alzheimer’s’ should not be applied.
Although these recommendations could be seen as 
merely a subtle extension of the neuropathological diagnos-
tic principles that Aβ and tau pathology are the definitive 
neuropathological ‘proof’ of AD, they are in fact a radical 
departure from the traditional use of the label ‘Alzheimer’s’ 
only when the AD cognitive phenotype is identified. Indeed, 
the publication by the workgroup runs the risk of formal-
ising the idea that AD cannot be hypothetically explained 
without accounting for the presence of Aβ and tau pathol-
ogy, as encapsulated in the following statement:
We emphasise though that A and T proteinopathies 
define AD as a unique disease among the many that 
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can lead to dementia. As a consequence, disease models 
where A and T are not in the primary causal pathway 
must provide a mechanistic explanation for the devel-
opment of both of these diagnostic proteinopathies, as 
well as neurodegeneration and clinical symptoms. [119]
This statement presents two major problems. First, it 
ignores contradictory literature on the absolute validity of 
Assumptions 1 and 2 (Box 1), which we discuss below in 
Questions 1–5. Second, it ignores equally valid alternate 
hypotheses of disease aetiology that do not require an Aβ 
(and/or tau) basis. We therefore view the statement as an 
inaccurate representation of the current state of AD research.
We do not see the problem lying with the hypothesis that 
Aβ and tau biomarkers could predict disease—it is a valid 
and testable idea. Instead, the crux of the problem is that this 
statement perpetuates the idea “A and T proteinopathies” 
define AD dementia as a priori fact, when this remains 
uncertain. Potentially more worrying is that in labelling “A 
and T proteinopathies” under the Alzheimer’s name in the 
absence of the cognitive phenotype, the inference is made 
that effective treatments for AD might now be defined by 
their ability to treat “A and T proteinopathies”, whether or 
not there is proven clinical benefit of such treatments.
Granted, the NIA-AA workgroup acknowledged disease 
causation may be independent of Aβ and tau, and went to 
considerable lengths to stress many clinicians and research-
ers do not necessarily wish to adopt proposed nomenclature 
(noting also that it is premature to extend these criteria to 
the clinic). However, busy clinicians and the public at large 
may not appreciate this subtle point. Instead, the take-away 
summary for most is likely to be that AD is to be defined 
and thus understood through an Aβ lens. Certainly, in the 
absence of other readily available biological markers of AD 
for clinicians, Aβ pathology may be a useful marker for AD 
dementia risk. However, as we discuss below, the literature 
suggests the causality of AD dementia is more complex than 
can be accounted for by the amyloid hypothesis.
Hence, these guidelines present a hypothetical idea, that 
in vivo measurements of Aβ (± tau) pathology can accurately 
predict disease, built upon another hypothetical idea, that 
Aβ and tau pathology mark a specific clinical disorder (AD 
dementia) and therefore provide clues to aetiology. In remov-
ing the safeguard of the clinical AD diagnosis, these recom-
mendations can be viewed as an attempt to bypass many long-
held concerns regarding the validity of these hypotheses. In the 
following we raise key questions testing Assumptions 1 and 2 
(Box 1), illustrating there is still significant discrepant evidence 
to address before concluding the presence of Aβ pathology is 
definitive for AD or aetiologically significant. If these assump-
tions are ultimately proven incorrect, the push to defining dis-
ease on their bases presymptomatically is running the risk of 
sending research into aetiology down the wrong path.
Question 1: Do cognitively normal 
individuals exhibit Aβ and tau pathology?
Answer: Pathological levels of Aβ and tau are 
present in cognitively normal individuals
In 1997 the unusual case of Sister Mary was introduced 
[250]. As part of the seminal longitudinal epidemiological 
‘Nun Study’, Sister Mary was described as a ‘gold stand-
ard’ for successful aging, owing to her high cognitive test 
scores at the advanced age of 101. Intriguingly, despite this, 
upon autopsy it was revealed her brain contained abundant 
amyloid plaques and NFTs, satisfying the Khachaturian cri-
teria for AD [143], but not the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) criteria [172]. 
Sister Mary therefore provided a conundrum: her amyloid 
plaques satisfied one of the neuropathological guidelines 
for AD, despite the fact she had no evidence of cognitive 
dysfunction.
Sister Mary is by no means unique, but representative of 
a group of individuals known variously as ‘high pathology 
controls’ (HPCs) [164], ‘preclinical AD’ [210], ‘asympto-
matic AD’ [219] or ‘non-demented but with AD pathology’ 
[233]. These individuals, despite being dementia free, can 
have amyloid plaque and NFT counts as high as those seen 
in individuals with mild cognitive impairment (MCI) or 
dementia [111, 112, 201]. Such cases, known since at least 
as early as 1933 [19, 270], are far from rare: one-third of 
the Nun Study cohort reached neuropathological criteria for 
AD, despite being cognitively intact at their last assessment 
before death [128, 251]. Other large-scale epidemiological 
studies have shown the same pattern [17, 192, 233, 235]. 
Collectively, up to 40% of cognitively normal individuals 
may reach some level of neuropathological criteria for AD 
[209], although this figure is dependent on age (possibly 
increasing from 10 to 40% between ages 50–90) and APOE4 
gene status [129].
It has been contended that end-stage NFT pathology 
(Braak stage VI) does not exist without some evidence 
of cognitive impairment [1, 188]. Nevertheless, evidence 
indicates as many as 20% of cognitively normal elderly 
exhibit neuropathological AD when restrictive diagnostic 
criteria for Aβ and tau pathology are applied [209]. Fur-
thermore, although late amyloid plaque and NFT stages 
are more common in clinical AD cohorts than the general 
population, not all symptomatic cases exhibit them [233], 
indicating neuropathological heterogeneity in symptomatic 
cohorts.
More recently, end-stage neuropathological findings 
have been supported by in vivo evidence that up to 47% 
of cognitively normal individuals may have amyloid 
positive positron-emission tomography (PET) scans (the 
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commonly quoted figure is ~10–30% [43, 44]) and 18% 
of older adults have tau PET scans reaching Braak stages 
III/IV [241].
The presence of amyloid plaques in cognitively 
normal individuals has not yet been explained
How to make sense of this pattern? It would be imprudent 
to ignore the many logical explanations for these well-
described paradoxical cases. Indeed, the hypothetical con-
cepts of ‘brain reserve’ and ‘cognitive reserve’ may have 
merit [257]. Alternatively, the location and type of plaque 
present (diffuse or neuritic) may be integral to the develop-
ment of disease. Otherwise, the popular amyloid ‘oligomer’ 
hypothesis suggests soluble amyloid species might be causal 
in AD, potentially mitigating the aetiological importance 
(and therefore presence) of insoluble species.
However, though these interpretations are valid, they all 
remain unproven. The concepts of ‘reserve’, for example, 
currently lack a neural basis [257], whilst both diffuse and 
neuritic plaques have been found in cognitively normal indi-
viduals [281]. The amyloid oligomer theory must also be 
tempered by the lack of consensus on the definition [16, 
263], definitive presence and biochemical composition [211, 
282] of Aβ oligomers in the brain in vivo and the question-
able validity of studies purporting oligomer toxicity, in part 
due to use of non-physiologically relevant experimental par-
adigms [179]. We also recall that solanezumab, developed to 
remove soluble forms of Aβ, did not meet primary endpoints 
in two phase III studies [66]. Collectively, therefore, the 
presence of purported disease-specific lesions in cognitively 
normal individuals remains unexplained. We refer the reader 
to Supplementary Material 1.2 for an expanded discussion 
of the various interpretations stated above.
Aβ pathology is a risk factor for AD, but does 
not guarantee it
Although unexplained, the evidence does suggest Aβ pathol-
ogy in cognitively normal and MCI is associated with a 
higher likelihood of progression to MCI or AD demen-
tia [51, 221]. Moreover, a correlation has been reported 
between amyloid PET positivity and subjective cognitive 
decline in cognitively normal elderly in some [3, 202] but 
not all studies [44, 45]. Others have reported amyloid posi-
tivity in cognitively normal individuals is associated with 
low memory scores, but not Mini Mental State Examina-
tion (MMSE) scores [130] (see [8, 182]). Furthermore, 
there have been recent suggestions that the relative amount 
of amyloid plaques (i.e. a dose-response) [22, 79, 94], or the 
rate of accumulation [153], rather than just amyloid ‘posi-
tive’ or ‘negative’ status, is linked to cognitive decline.
Hence, the presence of amyloid in cognitively normal 
individuals may be useful for predicting a risk of conver-
sion from non-symptomatic to symptomatic stages. How-
ever, these studies merely suggest Aβ pathology to be a risk 
factor for dementia, not necessarily a cause, let alone the 
sole cause. Some studies, for instance, have shown as high 
as 80% a non-conversion rate of amyloid positive cogni-
tively normal individuals to MCI or dementia 2–3 years later 
[280], with some individuals remaining cognitively stable 
for up to 6 years after follow-up [44]. Furthermore, other 
evidence suggests injury markers, rather than amyloid mark-
ers, are better predictors of progression from MCI to AD 
[276]. Collectively, these results suggest the utility of Aβ 
pathology alone to predict cognitive decline may be limited, 
questioning its applicability as a disease defining biomarker.
Question 2: Are there individuals diagnosed 
clinically with AD, but who have no Aβ 
and tau pathology?
Answer: Some individuals clinically diagnosed 
with AD do not have Aβ pathology
Discrepancies between the clinical phenotype and the neu-
ropathology of disease have long been known. Alzheimer’s 
second case, for instance, was one of plaque-only dementia, 
lacking tau tangles [174]. However, it was not until formal 
neuropathological guidelines were in place that systematic 
studies shed light on how widespread these discrepancies 
are. Reviewing the relationship of the clinical and neuro-
pathological diagnosis across 919 subjects at National Insti-
tute on Aging Alzheimer’s Disease Centres from 2005 to 
2010, Beach demonstrated a sensitivity of diagnosis rang-
ing from 70.9 to 87.3% and specificity of 44.3–70.8% [12]. 
Importantly, a substantial proportion (39%) of their ‘non-
AD’ dementia diagnoses exhibited AD histopathology, a 
finding corroborated in other studies [195]. Other signifi-
cant findings were that a number of clinical AD diagnoses 
had low levels of Aβ pathology and that 17 of 88 cases not 
meeting pathological criteria for AD were diagnosed with 
AD regardless [12].
Discrepancies in clinical and pathological diagnoses 
have been verified across multiple studies. Collectively, they 
report limited evidence of cerebral AD pathology in approxi-
mately 10–20% of individuals clinically diagnosed with AD 
[12, 245], although some studies report lower numbers [224] 
and others report higher. More recent studies continue to 
highlight disagreements. For instance, a 30% discrepancy in 
clinical and biomarker data was found in one of two tested 
cohorts using a novel blood based Aβ assay [187]. Addition-
ally, it has been illustrated there is inter-individual heteroge-
neity in the content and chemical characteristics of Aβ and 
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tau pathology in the hippocampus, even amongst patients in 
the same neuropathological stage [85].
Notably, as indicated by Beach, many individuals with a 
clinical diagnosis of AD exhibit mixed pathology (e.g. com-
binations of amyloid plaques, cerebral infarctions, Lewy bod-
ies, etc.). One large-scale longitudinal study found 46% of 
individuals with a clinical AD diagnosis had multiple pathol-
ogies [239], a finding corroborated by others (see [214]). This 
extends to dementia more broadly, where > 50% can exhibit 
mixed pathology [238]). More recently, >230 combinations 
of neuropathology were observed in a cohort of >1000 aged 
individuals [27]. Although amyloid plaque and NFT pathol-
ogy was common, it rarely occured in isolation [27]. This 
indicates co-morbidities are the rule rather than the exception 
[214, 271]. Importantly, the relative level of Aβ pathology 
may not differentiate Aβ-only dementia and mixed-pathology 
dementia cases. In one study [100], for instance, the CERAD 
criteria for a diagnosis of AD were satisfied in 83% of cases 
clinically diagnosed as Lewy body dementia. Furthermore, 
amyloid plaque density has been shown to reach the level 
required for the neuropathological diagnosis of AD in cases 
of early-onset dementia following TBI [139]. The implication 
is that Aβ biomarkers may have limited ability to selectively 
diagnose ‘pure’ Aβ and tau pathology-only individuals.
Collectively, the data above raises the question as to 
whether AD dementia can be accurately defined on the basis 
of Aβ neuropathology. We consider this further below.
Some individuals clinically diagnosed with AD 
exhibit non‑Aβ pathologies
Importantly, a portion of ‘clinically misdiagnosed’ cases 
(i.e. Aβ pathology-negative individuals with a clinical 
AD diagnosis) show non-Aβ pathologies in brain sections. 
These so-called ‘AD mimics’ include tangle-only dementia 
or argyrophilic grain disease, frontotemporal lobar degen-
eration, cerebrovascular disease, Lewy body dementia and 
hippocampal sclerosis [12].
The use of in vivo diagnostic techniques measuring 
other markers (e.g. NFTs, brain hypometabolism and atro-
phy) has corroborated these discrepancies. For example, 
hippocampal sclerosis of aging has been identified as an 
AD ‘mimic’, being present in > 20% of individuals over 85. 
A recent proposal suggests redefining this group as ‘cer-
ebral age-related TDP-43 and sclerosis’ (CARTS) [190]. 
Furthermore, many individuals clinically diagnosed with 
probable AD that have no or few amyloid plaques do 
exhibit NFTs, a phenomenon termed primary age-related 
tauopathy (PART) [55].
This AD mimicry concept is supported by about 25% of cog-
nitively normal individuals, and a similar proportion of those 
with mild cognitive impairment (MCI), over the age of 65, 
exhibiting abnormal neurodegeneration biomarkers, but normal 
Aβ biomarkers [122]. This entity has been termed ‘suspected 
non-Aβ pathology’ (SNAP) and is labelled thus irrespective of 
cognitive status. While these categories may or may not overlap 
[122, 178], their presence is telling in the present context.
Crucial questions emerge when seeking to understand the 
above clinical and pathological discrepancies. One obvious 
question is whether or not the neuropathological criteria 
used to diagnose AD are associated with the pathogenesis 
of the clinical condition. Another is whether individuals 
without evidence of Aβ pathology are being clinically mis-
diagnosed. For instance, are CARTS, PART and SNAP truly 
‘non-AD’, or are they merely ‘non-amyloid.’
In one study, cognitively unimpaired individuals with 
SNAP were found to be indistinguishable from amyloid posi-
tive individuals by both imaging and clinical criteria, as well 
as risk factor assessments [146]. Furthermore, separation of 
PART from AD has been disputed on the grounds that no 
neuropathological, genetic or clinical criteria differentiate 
such cases from early AD [70]. These arguments, debated in 
references [43, 55, 70, 122], are consistent with clinical AD 
sometimes being independent of Aβ pathology [12]. In this 
context it is important to note that both Aβ and non-Aβ pathol-
ogies associated with dementia account for less than half of 
all late-life cognitive decline, suggesting the field has barely 
scratched the surface of potential causes or contributors to 
cognitive decline, beyond histologically visible lesions [25].
In summary, the previous two sections illustrate (1) that 
cohorts of cognitively normal individuals can show Aβ and 
tau pathologies, implying amyloid deposition is not nec-
essarily causal; (2) that other cohorts diagnosed as ‘non-
AD’ dementias can exhibit amyloid plaques and tau tan-
gles, implying these lesions are not unique to AD, and (3) 
Aβ-negative cohorts diagnosed clinically as AD dementia 
can instead exhibit other pathologies, indicating pathogenic 
pathways to AD dementia unrelated to amyloid.
One could eliminate these discrepancies by ignoring 
the clinical diagnosis and relying solely on the presence 
of Aβ (± tau) pathology to define AD dementia. However, 
as we have discussed, the literature is not this simple. Fur-
ther understanding by the field, on which rational therapy 
depends, must face this issue.
Question 3: Does the spatial appearance, 
progression and absolute amount 
of amyloid plaques correlate with declining 
cognition more conclusively than other 
pathologies?
The short answer is that amyloid plaques do not correlate 
to dementia as well as do tau tangles or synapse pathol-
ogy. Arriving at this conclusion involves discussing spatial, 
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correlative (this section) and temporal dimensions (next sec-
tion) of the question.
Although the original neuropathological guidelines for 
AD were built on the correlation of amyloid plaques and 
NFT counts to cognition, much research since has estab-
lished amyloid plaques are less well correlated to the clinical 
and anatomical progression of AD than other pathologies, 
including synapse loss [266] and NFTs [184, 197]. One 
possible reason for the disparity between the hypothetical 
primacy of amyloid in disease and its relatively poor cor-
relation to clinical decline, compared with other patholo-
gies, could be the unreliability of the early statistical find-
ings [188, 265]. Nevertheless, evidence since has indicated 
neuritic plaques correlate to declining cognition better than 
do diffuse plaques [188], indicating that even if NFTs cor-
relate better, plaques counts are still useful determinants of 
dementia severity.
Why do NFTs correlate better than amyloid plaques? This 
may be due to the spatially distinct anatomical locations in 
which each of these pathologies arise, and then propagate. 
NFTs propagate fairly linearly, as denoted in the Braak 
staging guidelines [28, 175]. These changes possibly begin 
subcortically, with the first cortical appearance observable 
in the transentorhinal region, before spreading toward neo-
cortical regions [30], which correlates spatially better with 
areas undergoing degeneration than does the propagation of 
amyloid plaques. Amyloid plaque deposition initially begins 
in polymodal association cortices and spreads toward the 
allocortex (for summaries see [34, 38, 110]). Additionally, 
the deposition of amyloid plaques plateaus in later life [121] 
whereas the rate of neurodegeneration accelerates [124], 
suggesting the clinical symptoms couple to neurodegenera-
tion, rather than Aβ deposition.
The better correlation of NFTs justifies suggestions that 
therapeutically [89] and diagnostically [196] targeting tau 
pathology may be a better alternative to anti-Aβ approaches. 
There are some relevant caveats to these theories. Neuron 
loss in AD far exceeds the number of NFTs, suggesting they 
may not be causal [93, 256, 264]. Furthermore, it is well 
understood both amyloid plaques and NFTs are present in 
large numbers of the cognitively normal elderly, with NFTs 
almost universally present in aged individuals [55]. Indeed 
neurons may live for decades with tau pathology [30, 181].
How can the relatively poor spatial correlation of amy-
loid plaques to NFTs, synapse loss and neurodegeneration 
be explained in a theory maintaining amyloid is primary 
in aetiology? One theory, with growing support, holds that 
Aβ deposition may trigger prion-like seeding and propaga-
tion of tau pathology in functionally connected areas [277]. 
However, the spreading of aggregated tau does not neces-
sarily require the presence of amyloid deposits [70], and tau 
may enhance the deposition and toxicity of Aβ [207]. Theo-
retically AD could begin through self-propagation of Aβ 
aggregates via a prion-like seeding mechanism [134, 283], 
followed by propagation of disease through the aforemen-
tioned mechanisms (e.g. Aβ could be the ‘trigger’ and tau 
the ‘bullet’ [24]). Other possible explanations are discussed 
in Supplementary Material 1.3.
Several caveats accompany theories seeking to explain 
Aβ’s role in these complex ways. Most involve Aβ pathology 
appearing before other AD-associated pathologies, which is 
not yet definitive (see next section). Additionally, much of 
the debate has shifted to the relationship of soluble oligo-
meric Aβ and tau to disease, rather than insoluble species 
[52, 98, 244, 256], questioning the aetiological relevance of 
insoluble protein deposits. As mentioned earlier, theories 
regarding soluble Aβ and tau await a better understanding of 
their nature in vivo. Otherwise, a major caveat is the lack of 
in vivo investigation of other possible markers of the clinical 
AD phenotype, beyond Aβ and tau. We discuss promising 
alternatives below and under Question 4.
We also note that Aβ deposition occurs in the cerebrovas-
culature (cerebral amyloid angiopathy (CAA)) as well as in 
the brain parenchyma. CAA is present in up to 85–95% of 
individuals with AD, with 25% of AD brains having moder-
ate-to-severe CAA [73]. Importantly, some cortical atrophy 
in AD may be a consequence of CAA [9, 84], suggesting 
CAA may be an independent contributor to cognitive [26] 
and pathological alterations in AD [9], despite it often being 
left out of the aetiological discussion. CAA is discussed in 
more detail in Supplementary Material 1.3.
What pathological markers correlate with disease 
beyond Aβ and tau?
In the following section (Question 4), we discuss several 
non-Aβ and non-tau AD biomarkers worth exploring as 
predictors and markers of AD dementia. We briefly note 
here, in the context of spatial correlative studies, that mark-
ers of synapse and neuronal pathology may provide impor-
tant independent indicators of disease. For example, a study 
using a recently developed tau PET marker suggested glu-
cose hypometabolism (a proxy marker of neuronal function 
[120]) tracks the clinical progression of disease better than 
tau pathology [46]. This is critical, since the clinical symp-
toms of AD may be coupled with changes in glucose metab-
olism, or the rate of neurodegeneration, rather than Aβ and 
tau deposition [124]. Considering neurodegeneration is a 
likely physical cause of cognitive decline in AD [271, 286], 
both preceding and paralleling it [124], this is unsurprising.
Support for this comes from a cortical atrophy signature 
of volume loss in the hippocampus, medial and lateral pari-
etal cortex and temporal neocortex [127]. Furthermore, neu-
ron loss in the hippocampus, cerebral cortex and subcortical 
regions, and a concomitant increase in non-neuronal cell 
numbers, may be a differentiating feature between those with 
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pathology who are symptomatic and those with pathology 
who are not [5].
The relationship of neuronal degeneration to cognitive 
decline is further reflected by the strong correlation of syn-
apse dysfunction and loss to cognitive decline [62, 184, 
236, 266], with synaptic abnormalities in the hippocam-
pus, cingulate gyrus, entorhinal cortex, temporal cortex and 
frontal cortex particularly relevant to clinical AD demen-
tia [62, 106]. Although evidence shows synapse pathology 
can occur on both living and dead neurons [52] it remains 
unclear if synapse loss precedes neuronal death, or whether 
both pathologies have distinct pathways.
Given that learning and memory depend on synapse and 
neural function, it is not surprising Aβ pathology would cor-
relate less well to cognitive decline than synaptic and neuro-
degenerative changes. Indeed there is appreciable consensus 
that AD is, ipso facto, a synaptic disorder, even within the 
amyloid hypothesis [180, 243]. Thoughts differ, however, 
on how this synapse pathology arises [184]. Of course, 
alterations in Aβ are predicted by the amyloid hypothesis 
to precede and likely cause synapse pathology [120]. How-
ever, it must be borne in mind synapse dysfunction usually 
arises from perturbation in the physiological functions of 
cellular and molecular components within the multicellular 
synapse and extracellular matrix [49, 180] (discussed fur-
ther in Supplementary Material 1.3). This debate therefore 
clearly requires consideration of the temporal appearance of 
possible mechanistic drivers beyond Aβ.
Question 4: Is the temporal appearance 
of Aβ pathology the first biological sign 
of disease onset?
Answer: It is not yet conclusive that Aβ pathology 
is the first putative AD biomarker to emerge 
along the disease ‘continuum’
A widely held idea has been that anti-Aβ clinical trials have 
failed simply because treatments were commenced too late 
in the disease process [244]. The conceptual development 
of ‘preclinical [255]’ and ‘prodromal [2]’ states of AD has 
been a significant step forward in aiming to overcome this 
limitation [221]. The hunt has therefore been on to identify 
biomarkers capable of predicting disease development dur-
ing these early phases. Much of the focus has been on Aβ, 
which makes sense if looking to target Aβ removal early in 
the disease process. However, as discussed below, this has 
come at the cost of meaningful focus on what other biomark-
ers may objectively predict cognitive decline.
The most prominently tested markers to date include 
CSF Aβ measurements (as proxies for cerebral Aβ depo-
sition), cerebral PET amyloid imaging, CSF total and 
phosphorylated tau measurements (as proxy markers of 
cerebral NFTs), cerebral metabolism using FDG PET (as 
a proxy marker of neuronal activity) and measurements of 
cerebral atrophy using MRI [103]. A framework for the tem-
poral sequence of these putative AD biomarkers has been 
proposed [123] and novel data are often compared to it. This 
hypothetical sequence predicts the appearance of Aβ pathol-
ogy precedes other AD-associated pathologies. The validity 
of this hypothesis is assessed below.
Is Aβ pathology the first biomarker to become 
abnormal in autosomal dominant AD mutation 
carriers?
Carriers of autosomal dominant AD mutations (in APP, 
PSEN1 and PSEN2) provide a useful group to test hypo-
thetical biomarker sequences. Nevertheless, despite sugges-
tions these populations have provide support for hypotheti-
cal models (that amyloid biomarkers become abnormal first 
[119]), the raw data can be unconvincing. For instance, the 
case was made that increased CSF Aβ42 levels are present 
up to 30 years in advance of clinical onset in mutation car-
riers, and then begin declining 25 years prior, preceding 
changes in other biomarkers [11]. However, although show-
ing a trend, CSF Aβ42 levels were not statistically different 
compared to non-carriers at these time points. Instead, statis-
tically significant changes occurred just 10 years before pre-
dicted onset, temporally after statistically significant changes 
in CSF tau, hippocampal volume, cerebral Aβ deposition 
and plasma Aβ at 15 years prior. A follow-up study again 
found statistically significant differences in CSF Aβ42 (at 
10 years prior to predicted onset) were preceded by changes 
in other CSF markers including tau markers and a neuronal 
death marker VILIP-1 [75].
There is evidence that abnormal levels of CSF Aβ precede 
the development of metabolic, structural and tau alterations 
[82]. More recently, in extending findings from an earlier 
observational study [18], one study illustrated changes in 
cerebral Aβ pathology 20 years in advance of predicted 
onset, preceding metabolic and structural changes in some 
(but not all) brain regions, beginning in the precuneus (the 
hippocampus was a notable exception) [95]. Intriguingly, 
early hypermetabolism was noted alongside Aβ deposition 
in the earlier study, perhaps reflecting that metabolism and 
Aβ deposition are related to neuronal activity [18]. Further 
recent work with a novel in vivo tau tracer has provided 
evidence NFT pathology may lag cerebral Aβ pathology in 
PSEN1 mutation carriers [213]. If this finding is replicated 
(the validity of tau tracers are still being assessed [279]), it 
will provide strong evidence cerebral amyloid deposition 
precedes cerebral tau pathology in familial cohorts.
Collectively then, studies in autosomal dominant AD 
cohorts have established that Aβ, tau and neurodegeneration 
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biomarkers significantly differ in mutation carriers many 
years in advance of expected AD onset. Furthermore, the 
evidence amyloid biomarkers go awry first (amongst those 
tested so far) has strengthened, despite robust conclusions 
being limited by a lack of statistical significance at extreme 
ends of the expected age of onset distribution (which, as 
noted [75], must be interpreted with caution due to small 
sample sizes), inter-individual variability [168] and a lack 
of longitudinal assessment of multiple biomarkers concur-
rently. Studies are ongoing to overcome these limitations. 
For instance, a recent effort [168] has provided a longitudi-
nal intra-individual dataset of putative biomarkers, support-
ing that cerebral Aβ pathology is an early marker of disease, 
albeit also highlighting important differences compared with 
earlier cross-sectional studies. Important to reiterate is that 
although Aβ pathology may have temporal precedence, not 
all brain regions follow the same temporal pathological pat-
terns [95].
We note it would not be unexpected to observe abnormal 
Aβ measurements early in autosomal dominant cohorts, con-
sidering such mutations are known to alter Aβ production. 
The majority of PSEN1 mutations, for instance, reduce total 
Aβ levels compared to wild-type PSEN1 and favour Aβ42 
over Aβ40 production [260]. However, there are a number of 
important caveats to familial data sets: (1) not all autosomal 
dominant AD mutations have the same influence on Aβ pro-
duction [260]; (2) hypothetical biomarker trajectory models 
will be subject to change once comprehensive longitudinal 
studies are completed (and putative AD biomarkers beyond 
those currently available are assessed) and (3) the extrapo-
lation of results from these cohorts to all AD must only be 
done so with caution.
It is not yet clear Aβ pathology is the first biological 
sign of sporadic AD onset
Studies in the much larger population at risk for sporadic 
AD are more difficult to interpret. Aβ pathology often seems 
clearly detectable many years in advance of symptom onset 
in sporadic AD (potentially up to 20–30 years [129]). There 
is also some useful evidence CSF Aβ levels become abnor-
mal more often and likely earlier than do CSF tau or hip-
pocampal volume [125]. However, if indeed amyloid may 
change up to 30 years in advance of symptoms, there is 
also a clear possibility (and evidence) that tau pathology 
arises very early in the brainstem, possibly preceding cer-
ebral deposition of Aβ [29, 259]. Indeed, evidence suggests 
the appearance of NFTs precedes Aβ pathology in the vast 
majority of affected regions [225]. The use of novel in vivo 
tau selective PET tracers will shed further light on the spatial 
and temporal relationship of these pathologies [279] (see 
[126, 163] for recent examples).
Meanwhile, beyond Aβ and tau, it is impossible to con-
clude either are the first markers of disease onset due to the 
distinct lack of comprehensive investment in, and validation 
of, alternative possible AD biomarkers. We discuss this issue 
below.
Measuring multiple putative AD markers 
without bias may provide more accurate predictions 
of disease
A common limitation in temporal studies is a lack of 
assessment of currently available biomarkers, longitu-
dinally, at the same time, in the same individuals [95, 
154, 162], as well as investment in validating and testing 
biomarkers beyond those commonly used. This does not 
diminish the preceding efforts, which have been incred-
ibly arduous, but illustrates the difficulty in drawing firm 
conclusions from current data sets that will inevitably be 
highly subject to change as new information emerges (see 
[168] for a recent example). The value of assessing multi-
ple biomarkers together is exemplified by evidence show-
ing Aβ and tau pathology, alone, do not predict incipient 
cognitive decline 7.5 years before onset as well as a com-
bined value of the two [221].
A recent study comprehensively illustrated the utility 
of assessing a diverse range of putative biomarkers and in 
doing so highlighted the importance of non-Aβ pathologies 
in disease. In analysing over 7000 brain images and > 10 
putative biomarkers across > 1000 healthy and diseased 
subjects, Iturria-Medina et al., demonstrated that vascular 
dysregulation could be the earliest and strongest pathologi-
cal factor associated with AD, before Aβ deposition [115], 
contradicting the predictions of the hypothetical late-onset 
AD biomarker curves [123].
Another instructive example of a precedent is clusterin. 
As we have related previously [47] clusterin, one of the 
acute phase proteins, is intimately associated with onset, 
progression, and severity of human AD [267]. Unfortu-
nately, only the amyloid chaperone function of this protein 
was discussed, rather than its role as an acute phase protein, 
increased in vivo by extremely small doses of the inflamma-
tory cytokines TNF and IL-1 [99]. Clusterin was found to 
be raised 10 years earlier than fibrillar Aβ deposition. The 
relevant gene, CLU, is the second highest of a list of the 
15 top-rated genes linked to AD on the Alzgene web-based 
collection [193].
Clearly, it is becoming increasingly important to objec-
tively predict and diagnose disease using unbiased assess-
ments of multiple putative biomarkers [41]. Evidence for 
the efficacy of other non-Aβ and tau markers is discussed 
in the following.
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Could in vivo synaptic measures be useful 
for prediction and diagnosis?
Synapse loss is clearly a major correlate of cognitive decline 
in AD. We recognise synapse dysfunction and loss could 
be argued to be non-specific for AD dementia [236], since 
it is clearly present in other neurodegenerative conditions. 
However, few in vivo longitudinal studies have attempted to 
search for signature spatial or temporal patterns of synapse 
dysfunction and loss, or synaptic biomarkers than could spe-
cifically mark disease, or subsets of disease. This may be due 
to in vivo tools for measuring synaptic deficits having only 
recently become available [31, 42, 141, 150]. For a recent 
promising example of one attempt to separate subclasses of 
dementia using synaptic markers see [20]. Differentiating 
the mechanisms underlying synapse loss in subclasses of 
dementia and determining if these mechanisms drive spa-
tially distinct synapse pathology in different dementias will 
be an important next step.
The potential of these novel in vivo synaptic markers 
has recently been illustrated, with a reduction in hippocam-
pal density visible in AD compared to cognitively normal 
controls using PET imaging of synaptic vesicle glycopro-
tein 2A (SV2A) [42]. Furthermore, CSF measurements of 
neurogranin, a proxy measure of synaptic loss, may predict 
progression from prodromal states to AD. It appears better 
correlated with tau, rather than amyloid [141]. Some evi-
dence exists for synaptic alterations occurring before the 
appearance of Aβ deposition [80, 254], but it cannot be ruled 
out soluble forms of Aβ may be driving this pathology.
Considering synapse dysfunction is a strong correlate of 
disease, continuing to investigate the temporal and spatial 
progression of synapse pathology in vivo, relative to other 
pathologies, is a pressing priority for future research. Such 
studies could profoundly alter the understanding of disease; 
we may learn, for example, that amyloid deposition, perhaps 
in functionally connected areas, is a correlative marker of 
synapse dysfunction and loss, not the cause.
Validating and utilising putative AD biomarkers 
beyond Aβ and tau pathology may assist 
with disease prediction and provide novel 
therapeutic targets
Synapses aside, it is not difficult to hypothesise Aβ pathol-
ogy is a sometimes secondary factor to myriad upstream 
triggers. It has been demonstrated that physical, age-related 
and genetic perturbations might exacerbate Aβ deposition. 
Vascular damage [86], oxidative stress [191] and APOE4 
[160] are examples. It is well established, for instance, dif-
fuse amyloid plaques develop within hours of TBI [132] 
and plaque density years following TBI can reach the level 
required for a definite AD diagnosis [139], in spatially simi-
lar patterns to those seen in AD [242]. It is logical to con-
sider that if there are upstream triggers of Aβ pathology 
(which may also trigger Aβ-independent cognitive dysfunc-
tion in AD) then significant effort should be directed towards 
understanding the spatial, correlative and temporal patterns 
of the cellular and molecular biomarkers related to these 
upstream triggers.
Other biomarkers under development concern mitochon-
drial dysfunction [81], neuronal injury (visinin-like pro-
tein-1 [142]) and axonal injury (neurofilament light [292]), 
amongst others. In particular, studies using in vivo mark-
ers of neuroinflammation, a possible mechanistic driver 
underlying many disease-associated risk factors [50], have 
already elucidated significant findings. The PET tracer 
11C-deuterium-l-deprenyl (DED), a putative marker of 
astrocyte activation, has been shown to correlate with Aβ 
deposition decades before symptom onset, suggesting a very 
early activation of astrocytes in AD that may either drive, or 
be driven by, Aβ pathology [240]. Furthermore, one study 
illustrated that an early phase of microglial activation, 
detected using a translocator protein 18 kDa (TSPO) tracer, 
was associated with a small upregulation of Aβ pathology 
in vivo, but could be independent of Aβ and hence triggered 
by other factors [77]. Other promising examples of neuro-
inflammatory biomarkers are discussed in Supplementary 
Material 1.4.
Bacterial, viruses, fungi and other microbial 
infiltration may be upstream triggers of AD 
and associated pathologies
There is a long history of investigation into a connection 
between various microbes and AD. Research links bacteria 
[74], fungi [205] and viruses [218], supporting theories that 
AD is potentially caused by infectious agents [101, 117]. 
There is a well-documented history, for instance, establish-
ing clinical and pathological similarities in syphilitic demen-
tia, caused by Treponema pallidum, to AD dementia, dating 
back to Alzheimer’s time [171].
More recently, a study has shown a population of 
patients with herpes simplex virus infections had a 2.56-
fold increased risk of dementia. Remarkably, when com-
paring those treated with anti-herpetic medication to those 
not, the risk of dementia in these patients was reduced by 
90.8% [273]. A published commentary is available [116]. 
When regarding these studies, one should be mindful of 
research showing Aβ may be an anti-microbial peptide [96] 
and therefore potentially acting to combat infiltrating infec-
tious agents.
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Analyses of possible disease biomarkers should be 
conducted without preconceptions about temporal 
ordering
In summary, there are many risk factors for AD, all of 
which may contribute to disease through numerous cel-
lular and molecular mechanisms, independent of, or in 
combination with Aβ and tau. The research reviewed 
above reveals a present lack of longitudinal in vivo explo-
ration of promising avenues, beyond Aβ and tau. While 
we await such data it is crucial that no a priori decision 
is made to lump untested putative biomarkers within pre-
existing, but unproven, conceptions of temporal ordering. 
Instead, more balanced hypotheses of temporal biomarker 
profiles are required, acknowledging the importance of 
many other factors to disease initiation and progression. 
A recent effort by Tse and Herrup [272] provides a holistic 
example.
Question 5: How widely applicable are 
findings from autosomal dominant mutation 
carriers to sporadic AD?
Answer: Autosomal dominant AD may represent 
a different disease to sporadic AD
Although further studies are clearly indicated, the fact 
remains that neither the clinician, the neuropatholo-
gist, nor the electron microscopist can distinguish 
between the two disorders, except by the age of the 
patient.
Katzman [137]
Theories on the aetiology of autosomal dominant 
and sporadic AD are often grouped under the same 
banner, but this might not be correct
An important turning point for the field was the widespread 
acceptance of the assumption early-onset and late-onset 
AD were one and the same [137] (Assumption 2, Box 1). 
The story following this period is well known. It was 
expected for some time a familial component to early-onset 
AD was likely to exist (a later analysis of Alzheimer’s sec-
ond case suggested a familial predisposition [145]). Auto-
somal dominant AD mutations were eventually identified 
in the APP gene on chromosome 21. A second AD locus 
on chromosome 14 was found in genes encoding PSEN1 
and PSEN2. Mutations (and duplications, in the case of 
APP) in these genes were summarily linked to altered Aβ 
metabolism. In contrast to mutations in precursor genes 
for other AD-associated pathologies, such as tau [188], 
they have become gold-standard evidence of the amyloid 
hypothesis.
The impact of these discoveries has been profound. 
Many observational and therapeutic clinical efforts focus 
on cohorts harbouring these mutations [10] and preclini-
cal models of disease are designed primarily by expressing 
these mutations in mice [234]. However, the relevance of 
extrapolating data garnered from observational and thera-
peutic studies with autosomal dominant AD carriers to spo-
radic AD has become less tenable over time. Their influence 
is at odds with their extreme rarity and although phenotypic 
similarities exist, so do known differences, apart from age-
of-onset alone, as originally assumed [137]. Additionally, 
the vast array of genetic risk factors for AD, beyond auto-
somal dominant mutations, casts doubts on the idea all AD 
pathogenesis can be explained by the amyloid hypothesis. 
In light of this, we next discuss the validity of Assumption 
2 (Box 1).
The genetic causes and risk factors for familial 
and sporadic AD are largely unknown
It is important to emphasise the extreme rarity of currently 
known autosomal dominant AD mutations (in APP, PSEN1 
and PSEN2) and the lack of understanding of the major-
ity of familial AD. Early-onset AD is variably reported to 
represent some 1–10% of all AD [33, 294], and generally 
thought to be familial (possibly 10% autosomal dominant 
and 90% autosomal recessive [287]). However, up to 95% of 
early-onset AD cases remain genetically unexplained [33]. 
Clearly, much of the genetics of AD remains unresolved (see 
Supplementary Material 1.5 for extended statistics on the 
heritability of AD).
In fact, far from being simple and linear, as the amyloid 
hypothesis predicts, the genetics of AD are highly complex. 
Causal mutations can be autosomal dominant, but these 
could either be inherited or arise de novo in both early-onset 
AD and late-onset AD [155]. Mutations could be recessive 
or germline/somatic and expressed in a mosaic pattern [33], 
as has been illustrated with Trisomy 21 [208]. Furthermore, 
evidence is gathering for epigenetic contributions to disease 
[232].
The aetiology of AD dementia in autosomal 
dominant mutation carriers may be different 
to the aetiology of sporadic AD
Regardless of the frequency of known autosomal dominant 
AD mutations, two unresolved questions remain: (1) what is 
the exact aetiology within these cohorts and (2) how relevant is 
their aetiology to AD more broadly? In regard to question (1), 
675Acta Neuropathologica (2018) 136:663–689 
1 3
we have previously pointed out APP, PSEN1 and PSEN2 muta-
tions will have numerous effects on full-length APP processing 
and APP function, as well as effects on functions of a range of 
other proteins beyond APP [179]. Evidence has continued to 
corroborate this view. For instance, not all PSEN1 mutations 
have the same predicted influence on the direction of APP 
processing [260]. This suggests that various mutations may 
not all drive disease in the same manner. Indeed, it is under-
appreciated that many Aβ-independent disease mechanisms 
may be initiated by different autosomal dominant mutations. 
We provide some examples in Supplementary Material 1.5.
Although many similarities exist, autosomal dominant 
AD mutation carriers can have distinct pathological and 
clinical phenotypes, not only from the wider AD spectrum 
but from each other. This suggests that although they share 
broadly similar endpoints, they might not arrive there in the 
same way. Despite spatial distribution of neuropathology 
being similar between autosomal dominant and sporadic 
AD [159], Aβ pathology is more severe in autosomal domi-
nant AD [159], and some mutation carriers can have unique 
plaque types. For example, individuals with PSEN1 exon 9 
deletions frequently exhibit ‘cotton wool plaques’ lacking a 
compact amyloid core with little neuritic and glial involve-
ment [227]. Furthermore, Aβ42 deposition is increased in 
some autosomal dominant cases compared to sporadic AD 
[157]. In addition, recent research suggests that both auto-
somal dominant AD and Trisomy 21 can be differentiated 
from sporadic AD by a distinct pattern of early striatal and 
thalamic amyloid deposition [53]. On limited data, in vivo 
comparisons of tau pathology indicate some similarities and 
differences [213], but firm conclusions await more develop-
ment and use of in vivo tau tracers.
Others have shown distinctly different cognitive [198, 227, 
229, 247], neurological [227], metabolic [183] and biochemi-
cal [11, 200] presentations between autosomal dominant AD, 
early-onset AD (in general) and late-onset AD [58] (reviewed 
in [227, 247, 262]). Trisomy 21, too, once provided an impor-
tant pillar of support for the amyloid hypothesis, but several 
valid findings question its relevance to all AD (refer to Sup-
plementary Material 1.5 for extended discussion).
In summary, neither within autosomal dominant cohorts, 
nor between these cohorts and all AD, has either the aetiol-
ogy or the aetiological relationship been determined. The 
phenotypic differences between autosomal dominant AD and 
sporadic AD raise suggestions they may have unique, or only 
partially overlapping, aetiologies.
The genetic risk factors for AD are many, varied 
and may act through Aβ‑independent mechanisms 
to influence disease onset and progression
The numbers of possible Aβ-independent mechanisms of 
AD are magnified by the many risk factors being identified 
through large-scale GWAS studies. To date, variants in 
NOTCH3, MAPT, GRN, C9orf72, CLU, PICALM, CR1, 
MS4A4/MS4A6E, CD2AP, CD33, EPHA1, ABCA7, BIN1, 
and others [105, 152, 186, 246], have been implicated. As 
well as evidence some of these are linked to amyloid plaque 
pathology [248], other studies have shown that many are 
unlikely to be associated with plaques and NFTs. Indeed, 
they even associate with other common neuropathologies 
[78]. For example, a recent GWAS analysis of nearly 5000 
individuals illustrated only 12 of 21 risk loci for clinically-
defined AD dementia were corroborated in clinico-neuro-
pathologically defined AD brains [13].
Possible Aβ-independent disease mechanisms driven by 
genetic risk factors cluster in a few key pathways including 
cholesterol and lipid metabolism, cell adhesion pathways, 
immune system and inflammatory response and endocytosis 
(for detailed reviews see [90, 275, 278]). They also clearly 
associate with synaptic function: synaptic genes are sensitive 
to the aging process [64] and many genetic AD risk factors 
appear to have synaptic functions [275], including APP and 
PSEN1, implying synaptic pathology could be driven by per-
turbations to critical synaptic genes, independently of Aβ.
Of note, analysis of cell-specific expression patterns 
illustrated many AD-linked genes are expressed by specific 
cells, with microglia consistently highlighted (e.g. TREM2 
and TYROBP [293]). Alongside a new appreciation of the 
role of microglia at synapses, these findings have profoundly 
influenced our thinking, leading us to predict perturbations 
in homeostatic microglial functions at synapses, driven by 
many factors, could be playing a major role in AD aetiol-
ogy [179, 180] (see Supplementary Material 1.3 for more 
information).
Several putative protective genetic factors provide clues 
to broader AD aetiology. One in particular has generated 
enormous excitement: an alanine to threonine mutation adja-
cent to the BACE1 cleavage site on APP [133]. Although 
rapidly touted as substantial support for the amyloid hypoth-
esis (and it certainly appears so at first glance), such an inter-
pretation fails to appreciate many alternate theories for the 
protective mechanism. For example, being present in both 
full-length APP and secreted APP alpha (sAPPα) this muta-
tion could enhance the many synaptic, neuroprotective and 
neurotrophic functions of these molecules [173, 226]. Yet, 
this avenue has not been explored experimentally to date. As 
partial support for this possibility, sAPPα production trended 
towards an increase in carriers, and the cognition of carri-
ers was better conserved compared with non-carriers, even 
after removing known AD cases from the cohort [133]. We 
discuss aetiological implications of other protective genetic 
factors, including APOE2 and PU.1, in Supplementary 
Material 1.5.
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The genetic risk factors for AD do not all fit 
seamlessly within the amyloid hypothesis
Most researchers still place Aβ as central to the role of AD 
risk genes, despite the many possible Aβ-independent dis-
ease pathways these risk factors could be influencing. This 
belief heavily colours the interpretation of novel AD-asso-
ciated genes. For example, the evidence base for SORL1 to 
be recognised as a fourth autosomal dominant AD mutation 
has recently grown after finding that rare loss-of-function 
SORL1 mutations are associated with a younger age-of-onset 
and are absent in cognitively normal populations [215]. Ini-
tial proposals regarding the pathophysiology of these vari-
ants focus almost exclusively on a potential link between 
SORL1 and APP processing [4, 291], despite the many 
ways these variants could drive disease independently of Aβ 
[253]. Other well-characterised genetic AD risk factors such 
as TREM2 variants and APOE4 suffer similar fates [135, 
274]. For discussion of possible Aβ-independent mecha-
nisms of TREM2 variants and APOE4 pathogenicity refer 
to Supplementary Material 1.5.
In large part the collective drive to establish 
Aβ-dependent mechanisms for every genetic risk factor is 
likely a consequence of the Aβ-lenses through which we 
have all thought of this disease for most our working lives. 
Hence, if it is first asked what a new genetic variant does to 
APP processing, or Aβ, before alternate functional effects 
are considered, Aβ-dependent, rather than Aβ-independent 
mechanisms, are more likely to be found. In essence, this 
is classical confirmation bias, born from subconscious 
behavioural bias, driven perhaps by funding opportunities, 
together herding scientists toward the analysis of only one 
part of the picture [7].
A partial return to Kraepelin’s separation 
of early‑onset AD and late‑onset AD is warranted, 
but could now be based on genetics
The rarity and phenotypic differences of autosomal domi-
nant AD mutations have often led to suggestions autosomal 
dominant AD and sporadic AD may have different aetiolo-
gies [36, 38, 252]. A split in nosology could therefore be 
valid, despite Katzman’s call to group early and late-onset 
cases together in the times before any genetic factors were 
identified. Others continue to emphasise the similarities as 
evidence they continue to be aetiologically relevant to one 
another [10].
It is clear that the amyloid hypothesis is most relevant 
to autosomal dominant AD, notwithstanding possible 
Aβ-independent mechanisms contributing to pathogenesis 
in these cohorts. Hence, clinical and pathological similari-
ties between autosomal dominant AD and AD, generally, 
are important to the validity of the amyloid hypothesis in 
all AD. However, the idea that the amyloid hypothesis is 
correct for all AD is difficult to reconcile with long-standing 
and emerging evidence that autosomal dominant AD can be 
differentiated from the far more common sporadic condition 
by the clinician, neuropathologist and geneticist.
It is interesting to reflect that known autosomal dominant 
AD mutations may drive distinct diseases and, since autoso-
mal dominant AD is linked to early-onset, a partial return to 
Kraepelin’s original distinction between presenile and senile 
dementia, albeit involving genetics as well as age-of-onset, 
could be valid. The emergence of many genetic risk fac-
tors for sporadic AD supports this further through the valid 
hypothesis these genetic risk factors may be driving unique 
pathophysiological disease mechanisms, independent of Aβ.
Implications of Questions 1–5: the risks 
of labelling ‘Aβ pathology’ as ‘Alzheimer’s’
Many findings raise questions regarding the central 
role of Aβ in all AD: until this is resolved, caution 
is needed
This kind of genuine objectivity, while seemingly a 
necessary quality of any scientist in his field, is sys-
temically virtually precluded now more than 100 years 
later. In a modern era where science has to be sold 
to funding agencies in order for careers to be main-
tained if not advanced, where adherence to schools 
of thought is nakedly prejudicial, and where fealty to 
senior scientists has less to do with scholarship and 
innovation than political stratagem, it is somewhat 
refreshing to peruse the translated works. Moreover, 
Alzheimer was anything but a self-promoter, as the 
name of the disease that now bears his name was not 
put forth by Alzheimer, but his contemporary and boss 
at the University of Munich, Emil Kraepelin [4] (Fig-
ure 1.4). Alzheimer, for his part, went to great lengths 
to include the observations of others in his descrip-
tions:
Castellani and Perry [35]
Our motive for raising questions about the position of Aβ 
in AD nosology, aetiology and diagnosis is not to suggest 
Aβ has no role in AD, nor to suggest that therapeutically 
targeting Aβ may not ultimately prove to have some benefit. 
We do not refute a role for Aβ in AD aetiology [179] and we 
draw no such conclusion here. We have, for example, already 
reviewed its role as one of the secondary damage-associated 
molecular pattern molecules (DAMPs) that generate proin-
flammatory cytokines through activating Toll-like receptors 
(TLRs) [48] in a number of diseases. In other words, the role 
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of Aβ in health and disease remains an important basis of 
continuing research.
It is not yet known, however, exactly why Aβ accumulates 
in some individuals. For sporadic AD, the prevailing theory 
suggests failing clearance mechanisms [261], whereas in 
familial AD, altered proteolytic processing of APP may be 
the culprit, with the caveat not all autosomal dominant AD 
mutations have the same catalytic effect [260]. Alternatively, 
amyloid plaque pathology could be a “general type of tissue 
reaction” to a number of factors, as suggested some eight 
decades ago [223].
In this context, it is important to note also that although 
Aβ is often considered deleterious, no consensus exists yet 
on whether it is harmful, helpful [6, 149] or just a bystander 
[36, 166]. Some have suggested it is an antibacterial and 
antiviral [96], seals blood–brain barrier leaks and has roles 
in learning and memory, amongst other important physiolog-
ical functions [32], some of which could explain its deposi-
tion in the aging brain [156]. As we [179] and others [32, 87, 
177, 212] have previously pointed out, little is known about 
these roles, the physiological functions of the APP protein 
and other cleavage products of APP, or the physiological 
Fig. 2  The missing pieces of the puzzle in the chronological sequence 
of questions, assumptions and findings that lead to the current 
Aβ-centric ‘consensus’ Alzheimer’s disease diagnostic guidelines. 
Many problems with the evidence used to support the current consen-
sus diagnostic guidelines and the amyloid hypothesis still exist. 1. Aβ 
pathology does not correlate well spatially to areas undergoing atro-
phy. 2. Other pathologies correlate better (synapses, NFTs) but have 
not been as extensively studied. 3. Early-onset AD and late-onset AD 
might be different diseases based on evidence suggesting they can be 
distinguished in various ways. 4. AD may not be one single homog-
enous disorder. 5. Aβ pathology exists in cognitively normal individ-
uals. 6. Aβ pathology is lacking in some with AD dementia. 7. Aβ 
pathology is not unique to AD dementia. 8. It is not conclusive that 
Aβ pathology is, temporally, the first ‘biomarker’ of AD. 9. Deleteri-
ous mutations in many genes can be linked to Aβ, but not all of them 
necessarily mechanistically contribute to disease through an effect 
on Aβ metabolism. 10. Protective environmental and genetic factors 
are not necessarily mechanistically protective through some effect on 
Aβ. 11. Much of the genetics of familial AD remains unresolved. 12. 
Senescence, autophagy, genetic, microbial, lifestyle choices/environ-
mental and cardiovascular/traumatic injury risk factors are potential 
upstream ‘causes’ of AD, but their mechanism contribution to patho-
genesis is not necessarily through Aβ. 13. Apart from genetics, most 
evidence supporting the amyloid hypothesis comes from preclini-
cal research (toxicity studies, expression of human AD mutations in 
mice), much of which has dubious relevance to the human condition 
[179]. 14. Many valid alternate hypotheses of AD aetiology exist. 
15. Many other possible factors independent of Aβ that could pro-
vide clues to causality exist. 16. Other methods for defining disease 
in preclinical, prodromal and symptomatic stages that do not require 
a priori stratification on the basis of Aβ measurement may exist, and 
remain untested. NFTs neurofibrillary tangles, Aβ amyloid-β
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roles of presenilin proteins beyond APP processing. This is 
not to say that Aβ, or specific species of Aβ, do not also have 
deleterious functions, but that their role may be dynamic 
and more complex than toxicity alone. Further studies along 
these themes may help put Aβ’s role in disease in a different 
context.
Irrespective of Aβ’s relevance to aetiology, there are 
many discrepant findings that raise doubts regarding the 
long-held assumption Aβ pathology ipso facto defines AD 
dementia (Fig. 2). Considering this, in the following we dis-
cuss the risks inherent in failing to adequately question the 
assumptions on Aβ’s position in disease and suggest ways 
in which disease prediction and nosology could otherwise 
be approached.
Clinical practice and clinical/preclinical research 
heavily depend on the way AD is framed and getting 
it wrong has serious detrimental implications
Implications of the current approach for modelling 
of disease
The majority of preclinical models for AD have been based 
upon overexpression of autosomal dominant human AD muta-
tions in mice. Criticism has been levelled at these models 
[48, 179, 234]. For instance, a recent article suggested up to 
3000 publications may need to be re-evaluated due to over-
expression artefacts [230]. Regardless of the technical issues, 
data generated in these models is a priori a study of autoso-
mal dominant AD with unknown relevance to sporadic AD. 
Furthermore, when new genes or mechanisms are linked to 
AD they are invariably hypothetically considered and subse-
quently investigated in the context of their impact on Aβ. This 
represents a subconscious behavioural bias that can lead to 
confirmation bias [7]. Preclinical research must look beyond 
an Aβ-centric approach, taking cues from other AD risk fac-
tors and considering how these risk factors could mechanisti-
cally lead to cognitive loss in a truly unbiased manner.
Implications of the current approach for clinical research
The amyloid hypothesis has clearly held sway over the direc-
tion of interventional clinical trials [179] but this approach 
has so far proven unsuccessful [57, 136]. Neither has target-
ing of NFT deposits fared well to date [88]. Support for the 
amyloid hypothesis and current diagnostic guidelines for 
AD may well emerge from continuing clinical trials [56]. 
However, while any promising future results may provide 
impetus for pursuing such approaches further, it is important 
not to over-interpreting findings (Box 2). Crucially, while a 
positive result with an anti-Aβ agent will likely be seized 
upon as proof of the amyloid hypothesis, even positive out-
comes will not necessarily negate the messages we relay 
here (see Box 2). Meanwhile, it is important to bear in mind 
there is an absence of evidence that modifying the levels of 
putative AD biomarkers, such as Aβ and tau, predicts clini-
cal benefit. Therefore, even if such biomarkers are proven 
diagnostically useful, it should not be automatically assumed 
targeting them will provide therapeutic benefit.
For clinical research more generally, we suggest studies 
do not always have to be approached through an Aβ lens. 
It is extremely difficult to draw aetiological conclusions 
when experiments are designed to only include informa-
tion from individuals with both a clinical and pathological 
diagnosis of AD, but exclude individuals with a clinical 
diagnosis of AD without evidence of Aβ pathology. We 
stress the need to retain an open mind regarding the exact 
aetiology of the clinical AD phenotype and to reflect this 
more accurately in experimental designs and therapeutic 
approaches.
Implications of the current approach for clinical practice
The way AD has been framed over the last few decades is 
driving clinical practice despite the fact it remains hypo-
thetical. As a case in point, clinicians with knowledge of 
amyloid PET scans have changed diagnosis and treatment 
strategies [61], but we do not yet know if this was truly ben-
eficial for the patients. Furthermore, the ethical dilemma of 
passing a diagnosis of amyloid-positivity onto patients as a 
diagnosis of preclinical AD, and potentially imminent AD 
dementia, has not been thoroughly considered. Knowledge 
of biomarker status may lead to stigma [258] and anxiety 
[97]. It is therefore important to recognise that although 
such biomarkers may provide some measure of risk for dis-
ease, it is not yet clear that any individual biomarker alone 
defines clinical AD dementia, or that targeting them will 
provide therapeutic benefit. We discuss possible alternate, 
more holistic approaches to disease prediction, diagnosis 
and nosology, below.
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If not centred on Aβ, how could disease 
prediction and diagnosis be approached?
A multifaceted, unbiased approach to AD prediction 
best reflects the current knowledge base
Prediction, diagnosis and research in autosomal dominant 
AD can clearly be approached differently to sporadic AD, 
owing to complete penetrance in autosomal dominant cases. 
At this stage, however, there is a lack of a clear unifying 
cause for sporadic AD. A unifying cause (or causes) may 
be found and subsequently revolutionise disease prediction 
and diagnosis. Emerging and exciting evidence for viral, or 
other microbial causes of disease, for instance, could place 
Aβ as a sometimes secondary factor and potentially even a 
protective agent [116].
Meanwhile, in the absence of a breakthrough, we envis-
age a future circumstance in which AD prediction strategies 
incorporate the wide variety of AD risk factors including 
senescence, autophagy, genetics, lifestyle choices/environ-
ment (education, hypertension, obesity, hearing loss, smok-
ing, depression, physical inactivity, social isolation and 
diabetes [161]), or trauma (such as cardiovascular diseases 
(stroke and heart disease) and traumatic brain injury). In 
such a strategy, an aggregate score of these risk factors, 
adjusted for relative risk, could be obtained, but prediction 
would be unbiased toward any specific factor (e.g. agnostic, 
like the proposed ‘ATN’ system for biomarkers [118]). Bio-
logical factors, such as APOE4 or Aβ, could be incorporated 
into a risk matrix, but like any other factor would not be 
a priori required for prediction, better reflecting that AD 
dementia can arise in their absence and that they might be 
present in those not destined to develop disease.
Objective models could then be developed to determine 
how these risk factors converge. For example, it could be 
that these factors affect the penetrance of one or two key 
causative biological mechanisms, such as oxidative stress 
or neuroinflammation. It is possible convergent mechanistic 
links may be Aβ and tau however, as we have elaborated 
above, there is ample evidence to propose convergent links 
may also be non-Aβ/tau. Alternatively, the various risk fac-
tors may drive disease through multiple independent biologi-
cal mechanisms.
It is attractive to suggest such a predictive model could 
help explain the clinical heterogeneity [151, 290] than 
pathology alone has so far, or could help to define sub-
groups, as previously done so using biomarker profiles 
Box 2: Possible interpretations of future 
clinical trials with therapeutics based 
on the amyloid hypothesis
1. If a therapeutic based on the amyloid hypothesis 
achieves a significant positive result the field may 
have reached the stage, predicted by Castellani and 
Smith [39], that eventually, by weight of numbers, a 
significant result is found by chance.
2. A significant positive response, perhaps on slowing 
the rate of progression or alleviating symptoms, will 
provide evidence Aβ may play some role in disease 
aetiology, but will not prove it has a central role (i.e. 
it may provide only partial support of the amyloid 
hypothesis). As an example, the eventual acceptance 
of the fact that Helicobacter pylori, not stomach acid, 
caused stomach ulcers [165], did not necessitate 
throwing out all the data that suggested the bystander, 
stomach acid, has a role. It is feasible that in a similar 
way, the data on Aβ does not need to be disregarded, 
but rather may ultimately need to be framed within 
a different description of disease nosology that more 
conclusively reflects causality (see Supplementary 
Materials 1.1).
3. A continuing failure of therapeutics based on the 
amyloid hypothesis in Phase III clinical trials will 
provide evidence the amyloid hypothesis is not com-
pletely correct, or that Aβ pathology is upregulated 
for reasons unrelated to disease progression (e.g. 
possibly for a protective function, such as the anti-
microbial capabilities described in the text).
4. A large statistically significant and replicable effect of 
an anti-Aβ therapeutic in markedly slowing neurode-
generation and dementia progression, when applied 
to amyloid positive patients in the asymptomatic and/
or prodromal stages, will provide substantial support 
for the amyloid hypothesis.
5. Any positive, neutral, or negative result obtained in 
interventional clinical trials in autosomal dominant 
mutation carriers may not predict outcomes in spo-
radic AD cohorts. Because the aetiological relation-
ship between autosomal dominant and sporadic AD 
is not yet clear, the field must entertain the possibility 
they represent unique diseases which may ultimately 
need to be therapeutically approached in distinct 
ways.
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[113]. Therapeutically, treatments could be tailored to the 
individual (i.e. moving toward precision medicine), or to 
subgroups, such as those with a clearly heightened risk of 
AD mechanistically driven primarily by inflammation, lipid 
metabolism, or other.
Although a multifaceted, unbiased approach to disease 
prediction is clearly difficult to construct and validate both 
financially and scientifically, evidence of the utility of more 
holistic predictive systems already exists. The recently 
developed polygenic hazard score (PHS) [63] is leading the 
way in this regard. Furthermore, similar personalised, label-
free approaches have, unsurprisingly, already been suggested 
[237].
Multifaceted predictive approaches for AD 
do not have to involve Aβ or tau prestratification 
systems
Traditional measures of pathology can still form an impor-
tant part of prediction modelling, diagnosis and nosology. 
New research has, for instance, suggested tau filaments may 
adopt disease-specific folds [76] and there is much evidence 
that combined measures of Aβ and tau may be diagnosti-
cally useful [194], not withstanding the well-characterised 
clinico-neuropathological discrepancies discussed in detail 
above. However, seeing that it cannot yet be concluded 
Aβ-status accurately predicts disease onset, defines a spe-
cific disease state, or is aetiologically significant, is there 
any benefit to using the ‘Alzheimer’s’ name interchangeably 
with ‘Aβ pathology’?
One utility of stratification systems based on biomarkers 
is to identify cohorts of patients for specific observational 
and interventional trials. For instance, knowledge of Aβ sta-
tus allows refinement of patient enrolment into anti-Aβ trials 
by removing Aβ-negative individuals who are unlikely to 
benefit, and whose presence may therefore create statistical 
noise, from the study. However, it does not require the ‘Alz-
heimer’s’ label to stratify based on Aβ status—individuals 
can be stratified and studied without it. Furthermore, it can 
be argued better, unbiased approaches to predict and define 
disease (as discussed above) are not being fully explored as 
needed, when taking this approach.
There has always been an inherent risk of using Aβ 
pathology to define disease. Placing any individual with 
‘abnormal’ levels of Aβ under the ‘Alzheimer’s’ banner risks 
including individuals that may never develop AD dementia, 
or excluding individuals destined to develop it. For exam-
ple, had in vivo biomarkers been available to indicate Sister 
Mary’s abnormal amyloid plaque levels in life she may have 
been, under the recently proposed criteria [119], a candidate 
for clinical AD trials, despite hindsight telling us she would 
never have developed cognitive decline. A more complex, 
unbiased and multifaceted approach to disease prediction 
could have identified Sister Mary’s unlikely progression.
Furthermore, applying disease labels without previously 
determining if these pathologies truly represent a specific 
disease severely limits research investigating unifying 
theories in which individuals with or without other certain 
pathologies (such as hippocampal sclerosis, tauopathy, neu-
rodegeneration, Lewy bodies, Aβ, etc.), are, aetiologically, 
part of the same disease spectrum, with Aβ pathology being 
just one marker, albeit somewhat unreliable, for dementia 
risk.
With these thoughts in mind, throughout this article we 
have deliberating avoided, where possible, using terms such 
as ‘AD neuropathology’, the ‘neuropathological hallmarks 
of disease’, or some other variation, to refer to Aβ and/or 
tau pathology. Instead we have referred to them individu-
ally as ‘amyloid plaque’ or ‘Aβ’ pathology, ‘tau’ or ‘NFT’ 
pathology, or AD-related/associated, where appropriate. The 
reason should be evident: we are not yet convinced (based 
on current and emerging data) they alone can account for the 
complexity of clinical AD dementia, or are unique markers 
of AD dementia, particularly in the absence of symptomatic 
changes. The use of such terms buys into this assumption 
as a priori fact.
Getting back to basics: AD is a complex cognitive 
disorder
The advent of genetics and imaging has taken some empha-
sis away from the critical need to focus on developing better 
detailed methods to understand normal cognition, cognitive 
decline and the myriad of other issues occurring alongside 
AD and dementia more broadly. There are clearly limitations 
to cognitive testing regimens for dementia [102, 104, 206], 
indicating more sophisticated neuropsychological assess-
ments are required to better predict and define cognitive 
and other changes [21, 102, 217], particularly in preclinical 
stages of disease [182]. This would likely have a profound 
impact on predictive power [199]. In keeping with our sug-
gestions above, the approaches used to identify and differ-
entiate subtle early and subsequently progressive clinical 
phenotypes should be linked to disease risk factors using 
unbiased approaches.
We suggest, more broadly, that decades of advanced 
research in many disciplines could become better integrated 
with the dementia field. This would balance out the current 
emphasis on neuropathology. As an example, psychology 
research may lead to better detection of early clinical phe-
notypes, track progression of decline, or improvements due 
to intervention, and could become a major aspect of disease 
stratification [15].
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Disease nosology should evolve as our 
understanding of disease aetiology evolves
The proposals we make above suggests disease nosology 
may have to move away from definitions formed on the rela-
tively simple basis of associated pathologies, unless a direct 
causal link of any pathology to the development of a specific 
clinical phenotype emerges. This is not a new suggestion. 
The limitations of neuropathology-based disease definitions 
have long been considered [37], prominently so by David 
Rothschild from the late 1930s onward (reviewed in [285]). 
Indeed, some opinions hold that much of the discrepant data 
suggests the current framework of AD nosology has perpetu-
ated a myth about the true nature of the disease which could, 
instead, be considered as many diseases [284].
Moving forward it is imperative that AD nosology, par-
ticularly in presymptomatic stages, evolves as our under-
standing of disease aetiology becomes more complete, 
rather than in the absence of such evidence. Until then, the 
umbrella label ‘Alzheimer’s’ is perhaps best applied when 
there is symptomatic evidence of cognitive decline, rather 
than as a surrogate for Aβ pathology, reflecting the under-
standing there may be many unique pathogenic mechanisms 
underlying the development of AD dementia. Such a view 
would be better represented by an unbiased approach to pre-
diction and diagnosis based on myriad risk factors. In this 
light we reiterate our full agreement with the view that the 
whole person and clinical picture must be considered when 
diagnosing, treating and researching AD [161].
Principles to consider for AD research 
moving forward
The field has yet to achieve the challenge laid down by Rob-
ert Katzman in 1986; to understand the cause of disease 
before we can hope to prevent it [138]. We propose the fol-
lowing key points be critically considered and embraced 
going forward as the field looks to meet this challenge:
1. There is a significant body of new data in the field, much 
of which leads to questions surrounding the accuracy 
of current consensus diagnostic criteria for AD and the 
validity of the amyloid hypothesis supporting them. 
Although this does not negate the possibility that Aβ 
status could predict dementia risk and play some role in 
disease aetiology, it does question the perceived central-
ity of its role in all AD. Considering this, it is incorrect 
to perpetuate the idea Aβ causes disease or accurately 
defines it as a priori fact.
2. Considering the amyloid hypothesis is struggling to 
account for the complexity of AD, research into treat-
ment, prediction, diagnosis and aetiology should work 
to incorporate the contribution of many disease risk fac-
tors in an unbiased manner. Thus, studies of humans 
(and preclinical models) should not solely consider 
Aβ-positive individuals (and, in doing so call such indi-
viduals ‘AD’), but should instead continue to include 
clinically identified AD cohorts irrespective of risk fac-
tors or pathology, then attempt to parse the data accord-
ing to unbiased approaches.
3. The enormous effort to relate Aβ biomarkers to risk has 
not yet been met by studies of other possible biomarkers, 
such as neuroinflammation, vascular factors and syn-
aptic/neurodegeneration markers. Future investment in 
longitudinal biomarker research must be more equally 
distributed.
4. AD dementia may, ipso facto, be a synaptic disorder. 
The field must consider the mechanistic pathways to 
synapse dysfunction and loss are many and varied. To 
prevent the risk of confirmation bias, studies looking 
into the mechanistic drivers underlying the contribution 
of AD risk factors to pathogenesis should aim to do so 
using unbiased approaches.
5. Results from future clinical trials will, naturally, have 
a major influence on research directions. We caution 
against over-interpretation of clinical trial data as defini-
tive proof of the validity of any hypothesis of AD aeti-
ology (Box 2). In particular, extrapolating results from 
studies in autosomal dominant AD cohorts to the wider 
AD spectrum must only be done with extreme caution.
6. More attention must be placed on understanding the 
subtleties and complexities of cognitive decline. Inte-
grating the neuroscience and psychology of learning 
and memory, systems physiology, cardiovascular biol-
ogy and endocrinology, immunology and more into the 
field could revolutionise our understanding of disease. 
As eloquently relayed [161], considering the person as 
a whole is critical to successful intervention, a view we 
reiterate could be extended to disease nosology, aetiol-
ogy and diagnosis.
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